

FDA APPROVED FOR PRURIGO NODULARIS (PN)¹

 **nemluvio**[®]
(nemolizumab-ilto) for injection
30 mg

“Some see
sunglasses...
I saw back
scratchers.”

Relieve
itch fast—
with
clearer skin
that lasts.¹⁻³

**FAST ITCH
RELIEF,**
in some people,
as soon as
48 hours^{1,3*}

Not an actual patient.

*Results were achieved at 48 hours in 17.2% of patients with NEMLUVIO vs 3.7% with placebo. Data are from pooled post-hoc analysis of daily itch improvement reported in Phase 3 clinical studies. Itch improvement was defined as ≥ 4 -point improvement from baseline (PP-NRS scale). Do not make conclusions based on these results. Individual results may vary.^{1,3}

Important Safety Information

Indication: NEMLUVIO[®] (nemolizumab-ilto) is a prescription medicine used to treat adults with prurigo nodularis. It is not known if NEMLUVIO is safe and effective in children with prurigo nodularis under 18 years of age.

Please see Important Safety Information throughout, accompanying full Prescribing Information including Patient Information, or visit nemluvio.com.



Not an actual patient.

PN symptoms can have an **impact on your daily life.**^{4,5}

START THE CONVERSATION

Use this discussion guide to help your dermatology specialist understand the impact of your PN and if **NEMLUVIO** may be right for you.



The unrelenting itch of PN

can lead you to scratch with just about anything.

PN CAN CAUSE⁴⁻⁶:

- Intense and/or persistent itch
- Itchy raised nodules (bumps) that may bleed and heal slowly
- Pebbly, hard, or thick skin
- Inability to sleep or focus due to intense itch



DOWNLOAD THE GUIDE

by scanning the QR code

or [click here](#)

Please see accompanying full [Prescribing Information](#) including [Patient Information](#), or visit [nemluvio.com](#).

 **nemluvio**[®]
(nemolizumab-ilto) for injection
30 mg

When PN's out of hand, ask about

 **nemluvio**[®]
(nemolizumab-ilto) for injection
30 mg



Not an actual patient.

Important Safety Information

Do not take NEMLUVIO if you are allergic to nemolizumab-ilto or to any ingredients in NEMLUVIO.

Before taking NEMLUVIO, tell your healthcare provider about all of your medical conditions, including if you:

- are scheduled to receive any vaccination. You should not receive a live vaccine right before or during treatment with NEMLUVIO.
- are pregnant or plan to become pregnant. It is not known whether NEMLUVIO will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known whether NEMLUVIO passes into your breast milk and if it can harm your baby.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Please see accompanying full Prescribing Information including Patient Information, or visit nemluvio.com.

4

NEMLUVIO offers:



Fast itch relief,
in some people,
as soon as **48 hours**^{1,3*}



Long-lasting skin clearance²



Fewer sleepless nights^{2†}



Favorable safety profile¹



**~Once-monthly dosing
from the start**¹



**No reports of injection site
pain from NEMLUVIO in
the OLYMPIA clinical trials,
individual results may vary**⁷

*Results were achieved at 48 hours in 17.2% of patients with NEMLUVIO vs 3.7% with placebo. Data are from pooled post-hoc analysis of daily itch improvement reported in Phase 3 clinical studies. Itch improvement was defined as ≥ 4 -point improvement from baseline (PP-NRS scale). Do not make conclusions based on these results. Individual results may vary.^{1,3}

[†]Adults with PN reported sleeping better while on treatment with NEMLUVIO.²

 **nemluvio**[®]
(nemolizumab-ilto) for injection
30 mg

5

PN starts with signals
beneath the skin.⁸



**A KEY DRIVER OF
PN IS IL-31**

IL-31 is a protein in your body that sends signals which can lead to itch, inflammation, and skin barrier disruption^{8,9}



**IL-31 TRIGGERS ITCH
& INFLAMMATION**

With PN, your body can produce too much IL-31, flooding your nerves with signals that cause inflammation and a relentless urge to scratch^{8,10,11}




**IL-31 BREAKS DOWN
SKIN BARRIER**

IL-31 interferes with the normal development of skin cells, which can lead to the formation of nodules^{6-8,11-13}

Not an actual patient.
IL-31=interleukin 31.

NEMLUVIO is
designed to directly
block IL-31 signaling.¹



BLOCKS IL-31 SIGNALING

NEMLUVIO acts as a barrier, blocking the signaling from IL-31¹



**BLOCKS NERVE SIGNALS
CAUSING ITCH & SOOTHES
SKIN INFLAMMATION**

By blocking IL-31 signals, NEMLUVIO helps to stop the urge to scratch and reduce inflammation^{1,8,10}



**HELPS RESTORE
SKIN BARRIER**

NEMLUVIO allows your skin to heal and clear^{1,8}

Not an actual patient.

6 Please see accompanying full Prescribing Information including Patient Information, or visit nemludio.com.

 **nemludio**[®]
(nemolizumab-ilto) for injection
30 mg

Fast itch relief.^{1,3}

About half of adults using NEMLUVIO had significant itch relief by Week 16 (49% vs 16% with placebo).¹

NEMLUVIO quickly relieves the urge to scratch



in some people, as soon as

48 hours^{1-3*}

Itch-free or nearly itch-free

7 out of 10

adults were itch-free or nearly itch-free[†] over 1 year^{2,3}

Significant itch relief

8 out of 10

adults achieved and maintained significant itch relief[‡] over 1 year^{2,3}



Not an actual patient.



Better days and nights ahead

In clinical studies, NEMLUVIO helped most adults improve sleep and quality of life, as measured across factors such as the effect of PN on work, life, or social activities.²

^{*}Results were achieved at 48 hours in 17.2% of patients with NEMLUVIO vs 3.7% with placebo. Data are from pooled post-hoc analysis of daily itch improvement reported in Phase 3 clinical studies. Itch improvement was defined as ≥ 4 -point improvement from baseline (PP-NRS scale). Do not make conclusions based on these results. Individual results may vary.^{1,3}

[†]Itch-free or nearly itch-free was defined as less than 2 on the PP-NRS, where 0 was no itch and 10 was worst itch imaginable.⁶

[‡]Significant itch relief was defined as an itch improvement of at least 4 points on the PP-NRS.¹

PP-NRS=Peak Pruritus Numerical Rating Scale.

Please see accompanying full Prescribing Information including Patient Information, or visit nemluvio.com.

Important Safety Information

NEMLUVIO may cause serious side effects, including: allergic reactions (hypersensitivity). Stop using NEMLUVIO and tell your healthcare provider or get emergency help right away if you get any of the following symptoms: breathing problems or wheezing; swelling of the face, lips, mouth, tongue, or throat; fainting, dizziness, feeling lightheaded; fast pulse; swollen lymph nodes; joint pain; fever; skin rash (red or rough skin); nausea or vomiting; general ill feeling; cramps in your stomach area.

 **nemluvio**[®]
(nemolizumab-ilto) for injection
30 mg

Skin clearance that lasts.^{1,2}

More than half of adults in
clinical trials had **PN nodules**
healed at Week 16.¹

BEFORE TREATMENT



31-year-old female.
Actual patient from clinical trial.

AFTER TREATMENT



Individual results may vary.

NEMLUVIO was studied in the largest clinical trial program of PN to date¹⁴

- Over 550 adult participants with moderate-to-severe prurigo nodularis¹
- Studies evaluated measurements of itch, skin clearance, and effect on sleep, among other factors^{1,2}

NEMLUVIO was evaluated in 2 phase 3 clinical trials and a long-term study. Results shown are from the second clinical trial* and the long-term study.²

*This clinical trial was called OLYMPIA 2.²

[†]Clear or almost clear skin was defined as a 1 or below on the Investigator's Global Assessment (IGA) scale, where 0 was clear and 4 was severe, with a 2-point improvement from baseline.¹

- Many of those using NEMLUVIO in clinical trials achieved **clear or almost clear skin[†]** at Week 16¹
- **75%+ clearer skin:** After 1 year with treatment, most adults in clinical trials had the majority of PN nodules healed^{1,2}

The most common side effect for adults using NEMLUVIO was headache (only 6% vs 3% with placebo). Atopic dermatitis and eczema were also seen in more than 1% of adults using NEMLUVIO and more common than placebo.¹

Please see accompanying full Prescribing Information
10 including Patient Information, or visit nemluvio.com.

 **nemluvio**[®]
(nemolizumab-ilto) for injection
30 mg

~Once-monthly dosing
from the start¹



Uniquely designed **with you** in mind.

NEMLUVIO is the first and only self-injectable treatment for PN that you can take approximately once a month from the start.^{1,15}



- Subcutaneous (under the skin) injection with a convenient prefilled self-injector pen you can use at home¹



- NEMLUVIO is **NOT** a steroid, cream, or immunosuppressant and requires no preliminary lab evaluations or ongoing lab monitoring¹



- Recommended dose for adults:
One 30-mg injection every 4 weeks after two initial 30-mg injections¹
OR
Two 30-mg injections every 4 weeks for adults weighing more than 198 lb (90 kg)¹



Easy to take on the go: NEMLUVIO can be stored at room temperature up to 77°F (25°C) for up to 90 days.¹

- Note the date you remove NEMLUVIO from the refrigerator. NEMLUVIO may be stored in the refrigerator at 36°F to 46°F (2°C to 8°C) until the expiration date¹



LEARN TO USE NEMLUVIO

by scanning the QR code
or [click here](#)

Review the NEMLUVIO Instructions for Use with your dermatology specialist before you start injections.

For additional support, ask about injection training with GPS (Galderma Patient Services) for NEMLUVIO™.



KEY QUESTIONS TO ASK YOUR DERMATOLOGY SPECIALIST

- 1 | Is NEMLUVIO right for me?
- 2 | How does NEMLUVIO work to relieve PN itch?
- 3 | How is itch relief with NEMLUVIO different than other treatments I've tried?
- 4 | When can I expect to see results with NEMLUVIO?
- 5 | What are the common side effects of NEMLUVIO?

Important Safety Information

The most common side effects of NEMLUVIO include: headache and skin rashes: atopic dermatitis (a type of eczema), eczema, and eczema nummular (scattered circular patches).

These are not all of the possible side effects of NEMLUVIO.

GPS⁺ for nemluvio[®]

GALDERMA PATIENT SERVICES

GPS (Galderma Patient Services) for NEMLUVIO™ is here for you with all kinds of support, including help with learning about your prescription, understanding insurance benefits, and co-pay assistance.



With Co-Pay Assistance, eligible patients may **pay as little as \$0***

*Out-of-pocket cost reductions for eligible patients may vary.

For Co-Pay Program Enrollment:

call **1-855-NEMLUVIO**,
visit <https://galdermaps.iassist.com>,
or scan the **QR code**



Not an actual patient.

14 Please see accompanying full Prescribing Information including Patient Information, or visit nemluvio.com.

More support along the way

Talk to your dermatology specialist or the **GPS for NEMLUVIO™** support team to learn more about the other programs that may be available to you.



QUICK START

Those who qualify are able to start NEMLUVIO sooner as their dermatology specialist works with insurance providers to secure approval



BRIDGE PROGRAM

Helps you access NEMLUVIO if you have a lapse in treatment due to change or loss of insurance, delayed re-authorization, or have exhausted Quick Start supply during insurance transitions or delays



PATIENT ASSISTANCE PROGRAM

Helps if you do not have any insurance, your insurance will not cover NEMLUVIO, or your insurance co-pays will create a financial burden and there are no other programs available to help*

*See eligibility requirements and terms of use.



NURSE NAVIGATORS

Nurse navigators are available online or over the phone to provide injection training and ongoing support

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

 **nemluvio[®]**
(nemolizumab-ilto) for injection
30 mg

Ask your dermatology specialist if NEMLUVIO could be right for you.

GET STARTED WITH GPS FOR NEMLUVIO TODAY

Learn more about support from GPS (Galderma Patient Services) for NEMLUVIO™ and how to complete enrollment at nemluvio.com.

For more information, you can call 1-855-NEMLUVIO, 8:00 AM – 8:00 PM ET, Monday – Friday.



SCAN OR CLICK TO STAY CONNECTED

Sign up to receive ongoing education, guidance, and resources to help along your treatment experience with NEMLUVIO.

References: **1.** NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P.; August 2024. **2.** Legat F, et al. Nemolizumab in prurigo nodularis up to 100 weeks: OLYMPIA LTE interim analysis. *JEADV*. 2025; doi:10.1111/jdv.70266. **3.** Ständer S, et al. Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis Phase 3 studies. *JEADV*. 2025; doi:10.1111/jdv.70250. **4.** Ludmann P. Prurigo nodularis. American Academy of Dermatology Association. Updated April 1, 2025. Accessed April 21, 2025. <https://www.aad.org/public/diseases/a-z/prurigo-nodularis-overview> **5.** Rodriguez D, Kwatra SG, Dias-Barbosa C, et al. Patient perspectives on living with severe prurigo nodularis. *JAMA Dermatol*. 2023;159(11):1205-1212. doi:10.1001/jamadermatol.2023.3251 **6.** Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. *Expert Rev Clin Pharmacol*. 2021;14(1):67-77. doi:10.1080/17512433.2021.1852080 **7.** Kwatra SG, Yosipovitch G, Legat FJ, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. *N Engl J Med*. 2023;389(17):1579-1589. doi:10.1056/NEJMoa2301333 **8.** Nemmer JM, Kuchner M, Datsi A, et al. Interleukin-31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. *Front Med (Lausanne)*. 2021;8:639097. doi:10.3389/fmed.2021.639097 **9.** Taber's Online Medical Dictionary. 2000-2025. Accessed April 18, 2025. <https://www.tabers.com/tabersonline/view/Tabers-Dictionary/758967/all/cytokine?q=cytokine> **10.** Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. *Front Med (Lausanne)*. 2021;8. doi:10.3389/fmed.2021.638325 **11.** Yosipovitch G, Misery L, et al. Skin barrier damage and itch: review of mechanisms, topical management and future directions. *Acta Derm Venereol*. 2019;99:1201-1209. doi:10.2340/00015555-3296 **12.** Mullins TB, Sharma P, Riley C, et al. Prurigo nodularis. In: *StatPearls*; Treasure Island (FL): StatPearls Publishing; March 1, 2024. **13.** Bewley A, et al. Prurigo Nodularis: A review of IL-31RA blockade and other potential treatments. *Dermatol Ther (Heidelb)*. 2022;12:2039-2048. doi:10.1007/s13555-022-00782-2 **14.** Galderma phase III data published in The New England Journal of Medicine: full Olympia 2 trial results demonstrate nemolizumab's rapid onset of action in patients with prurigo nodularis. Galderma Laboratories, L.P. Press release. Published October 26, 2023. Accessed April 18, 2024. **15.** DUPIXENT. Prescribing information. Sanofi Genzyme; 2024.

Please see Important Safety Information throughout, accompanying full Prescribing Information including Patient Information, or visit nemluvio.com.



FOLLOW US ON SOCIAL



@nemluvio_nemolizumab



@NEMLUVIO® (nemolizumab-ilto)

GALDERMA
EST. 1981

©2026 Galderma Laboratories, L.P. All Rights Reserved. NEMLUVIO is a registered trademark of Galderma. US-NPN-2500015 01/26